Going on a Drug Holiday?

Journal of Clinical Densitometry

Volumn 14, Issue 4, 2011, Pages 377-383

  Bonnick, Sydney Lou ^a,b  

^a Clinical Research Center of North Texas   (United States)

^b UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; BARRETT ESOPHAGUS; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CREATININE CLEARANCE; DISEASE DURATION; DRUG APPROVAL; DRUG DEPRIVATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; ESOPHAGUS CANCER; FEMUR SHAFT FRACTURE; FRACTURE; HIP FRACTURE; HUMAN; NEPHROTOXICITY; OSTEOLYSIS; POSTMARKETING SURVEILLANCE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SPINE FRACTURE; TREATMENT DURATION; TREATMENT OUTCOME;

ALENDRONATE; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ESOPHAGEAL NEOPLASMS; ETIDRONIC ACID; FEMORAL FRACTURES; HIP FRACTURES; HUMANS; IMIDAZOLES; KIDNEY; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RENAL INSUFFICIENCY; RISK ASSESSMENT;

EID: 82855181994     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2011.07.006     Document Type: Editorial

References (33)

1. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535-1541.
2. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 1999, 282:1344-1352.
3. Chesnut C.H., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
4. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
5. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment. JAMA 2006, 296:2927-2938.
6. Schwartz A.V., Bauer D.C., Cummings S.R., et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010, 25:976-982.
7. Bone H.G., Hosking D., Devogelaer J.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350:1189-1199.
8. Watts N.B., Chines A., Olszynski W.P., et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008, 19:365-372.
9. Black DM, Reid I, Cauley J, et al. The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). 32nd American Society for Bone and Mineral Research annual meeting, Toronto, Ontario, Canada. Presented October 16, 2010. Abstract available at: Accessed: May 12, 2011. http://www.asbmr.org/Meetings/AnnualMeeting/Abstracts10.aspx.
10. Black D.M., Reiss T.F., Nevitt M.C., et al. Design of the fracture intervention trial. Osteoporos Int 1993, S3:S29-S39.
11. Sorensen O.H., Crawford G.M.M., Mulder H., et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003, 32:120-126.
12. Mellstrom D.D., Sorensen O.H., Goemaere S., et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 75:462-468.
13. Pendrys D.G., Silverman S.L. Osteonecrosis of the jaws and bisphosphonates. Curr Osteoporos Rep 2008, 6:31-38.
14. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491.
15. CIOMS Guidelines for preparing core clinical safety information on drugs. Report of CIOMS Working Group III 1995, Council of Organizations of Medical Sciences, Geneva, Switzerland.
16. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005, 23:8580-8587.
17. Hoff A.O., Toth B.B., Altundag K., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008, 23:826-836.
18. Pazianas M., Miller P., Blumentals W.A., et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors and clinical characteristics. Clin Ther 2007, 29:1548-1558.
19. Lyles K.W., Colón-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
20. Orwoll E.S., Miller P.D., Adachi J.D., et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010, 25:2239-2250.
21. Reid D.M., Devogelaer P., Saag K., et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomized controlled trial. Lancet 2009, 373:1253-1263.
22. Barrett-Connor E., Swern A.S., Hustad C.M., et al. Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. Osteoporos Int 2011, In press.
23. Lewiecki E.M., Cooper C., Thompson E., et al. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract 2010, 64:821-826.
24. FDA. Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates. Available at: Accessed: May 12, 2011. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm136201.htm.
25. Miller P.D. The kidney and bisphosphonates. Bone 2011, 49:77-81.
26. FDA Zoledronic acid. Reports of acute renal impairment and failure associated with once-yearly intravenous treatment for osteoporosis in postmenopausal women. Drug Safety Newsletter 2009, 2:13-15.
27. Boonen S., Sellmeyer D.E., Lippuner K., et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008, 74:641-648.
28. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360:1789-1792.
29. Cardwell C.R., Abnet C.C., Cantwell M.M., Murray L.J. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010, 304:657-663.
30. Green J., Czanner G., Reeves G., et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010, 341:c4444.
31. Nieves J.W., Bilezikian J.P., Lane J.M., et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010, 21:399-408.
32. Shane E., Burr D., Ebeling P.R., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
33. Schilcher J., Michaëlsson K., Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011, 364:1728-1737.